What questions should I ask my doctor at my next appointment about Spindle Cell Sarcoma

Questions to Ask Your Doctor About Marlo's Spindle Cell Sarcoma

Based on Marlo's [ID removed] here are targeted questions organized by topic that will help you have a more productive conversation with your care team:

ABOUT THE DIAGNOSIS & TUMOR BIOLOGY

1. Clarifying the exact diagnosis:

   • "The pathology reports mention a 'low-grade spindle cell neoplasm of myofibroblastic origin' with cartilaginous metaplasia. Can you explain what this means for Marlo's prognosis and treatment options?"
   • "Why did we need consultations from Mayo Clinic and St. Jude to confirm the diagnosis? What makes this tumor challenging to classify?"

2. Understanding the EGFR mutation:

   • "Marlo's testing shows an EGFR ITD (internal tandem duplication) and KDD (kinase domain duplication). How common is this in spindle cell sarcomas, and what does it tell us about treatment options?"
   • "Does this EGFR mutation mean Marlo might respond to EGFR-targeted therapies like afatinib or other inhibitors?"

3. About the tumor microenvironment:

   • "The immunostaining shows this is a 'cold' tumor (low immune infiltration). What does that mean for immunotherapy options, and can we change that?"

---

ABOUT MOLECULAR TESTING & WHAT'S BEEN DONE

1. Clarifying test results:

   • "We've done exome sequencing, whole genome sequencing, RNA-seq, and immunostaining. What are the most important findings from these tests that should guide treatment?"
   • "Are there any other genetic mutations or biomarkers we should test for that might open up additional treatment options?"

2. About the testing plan going forward:

   • "The treatment strategy document mentions organoid development, PDX models, and drug screening. When will these be ready, and how will results change Marlo's treatment plan?"
   • "Should we do another biopsy before starting new systemic therapy, or can we use the tissue we already have?"

---

ABOUT RADIATION THERAPY

1. Radiation strategy (from your Decision 1):
   • "Is conventional external beam radiation recommended for Marlo's tumor location and biology?"
   • "Have you considered carbon ion radiation therapy (CIRT)? Is it available and appropriate for this tumor type?"
   • "Should radiation happen before or after systemic therapy? How does that affect surgical planning?"

---

ABOUT SYSTEMIC THERAPY OPTIONS

1. Current and future drug options:

   • "The strategy document mentions switching to afatinib (an irreversible EGFR inhibitor). What evidence supports this change, and what would you need to see before making that switch?"
   • "Should we consider adding a MET inhibitor to target potential resistance mechanisms?"
   • "Are there any clinical trials specifically for EGFR-altered sarcomas that Marlo might be eligible for?"

2. About combination approaches:

   • "Could we combine targeted therapy with immunotherapy or other approaches to make the tumor more responsive?"

---

ABOUT IMMUNOTHERAPY & VACCINE APPROACHES

1. Immune-based strategies:
   • "Given that Marlo's tumor is 'cold' (low immune infiltration), what approaches could convert it to 'hot'?"
   • "Is there a neoantigen-based cancer vaccine being considered? What would that involve?"
   • "Are there checkpoint inhibitors (like anti-PD-1) that might help, either alone or combined with other therapies?"

---

ABOUT CLINICAL TRIALS & SPECIALIZED TREATMENTS

1. CAR-T and other trials:
   • "St. Jude has a B7-H3 CAR-T trial (3CAR). Is Marlo eligible, and would this be appropriate now or after other treatments?"
   • "Are there any ADC (antibody-drug conjugate) trials targeting EGFR or other markers that Marlo should consider?"
   • "What about FAP-targeted radioligand therapy? Are there centers in the US or internationally that treat pediatric sarcomas with this approach?"

---

ABOUT SEQUENCING & TIMING

1. Treatment sequence:
   • "What is the optimal order for these different treatments? Which decisions are time-sensitive?"
   • "How do we prioritize between systemic therapy, radiation, surgery, and experimental approaches?"
   • "Should we wait for organoid/PDX drug screening results before changing therapy, or move forward with what we know now?"

---

ABOUT MONITORING & FOLLOW-UP

1. Surveillance and response assessment:
   • "How will we measure whether treatment is working? What imaging or blood tests will you use?"
   • "According to NCCN Guidelines for soft tissue sarcomas, what surveillance schedule should Marlo follow?"
   • "How often should we reassess and potentially change the treatment plan?"

---

ABOUT RESOURCES & SUPPORT

1. Accessing specialized expertise:
   • "Should we seek a second opinion from a pediatric sarcoma specialist at a major center (like St. Jude, Dana-Farber, or Memorial Sloan Kettering)?"
   • "Are there sarcoma-specific support resources or patient communities we should connect with?"
   • "How do we access the specialized testing services mentioned in the treatment strategy (TRACER, BostonGene, Certis, etc.)?"

---

PRACTICAL QUESTIONS

1. About side effects and quality of life:

   • "What are the expected side effects of [specific therapy], and how will we manage them?"
   • "How will treatment affect Marlo's daily activities, school, and development?"

2. About insurance and access:

   • "Will insurance cover the specialized testing and treatments being considered?"
   • "Are there compassionate use or expanded access programs if standard options don't work?"

---

KEY DOCUMENTS TO BRING

Consider bringing or referencing:

• Marlo's Treatment & Research Strategy document - shows the comprehensive plan your team is considering
• Pathology reports from CHLA and Mayo Clinic - for discussion of the diagnosis
• Molecular testing results - to discuss EGFR mutations and other findings
• List of questions - so you don't forget anything in the appointment

---

WHY THESE QUESTIONS MATTER

According to NCCN Guidelines for Soft Tissue Sarcoma, optimal management requires:

• Clear understanding of histologic subtype and grade
• Comprehensive molecular characterization to identify treatment targets
• Multidisciplinary team coordination (surgery, radiation, medical oncology)
• Individualized treatment planning based on tumor biology and patient factors

Your medical team has already done extensive work to understand Marlo's tumor. These questions will help you understand their thinking and ensure you're all aligned on the next steps.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.